Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19

• Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.

Detalles Bibliográficos
Autores principales: Liontos, Michalis, Kaparelou, Maria, Karofylakis, Emmanouil, Kavatha, Dimitra, Mentis, Andreas, Zagouri, Flora, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390730/
https://www.ncbi.nlm.nih.gov/pubmed/32766415
http://dx.doi.org/10.1016/j.gore.2020.100615
Descripción
Sumario:• Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.

Ejemplares similares